Capricor Therapeutics Faces Securities Class Action Lawsuit
Attention investors! A securities class action lawsuit has been initiated on behalf of investors who acquired shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024, and July 10, 2025. This legal action was launched to address serious allegations regarding the company's misrepresentation of critical data.
Understanding the Allegations
The lawsuit alleges that the index had misleading information pertaining to the safety and efficacy data from their Phase 2 HOPE-2 trial study of deramiocel, a leading cell therapy designed to treat cardiomyopathy, particularly for those affected by Duchenne muscular dystrophy.
Why is This Important?
For investors, details regarding the efficacy of treatments under development are paramount. Misleading information could greatly impact financial investments and personal stakes in the company’s future. Thus, those who purchased shares during this time frame may have experienced losses and should seriously evaluate their options.
Are You Affected by This Situation?
It’s essential to ask yourself a few important questions. Did you own shares of Capricor Therapeutics during the specified period? Have you suffered financial losses as a result? If the answer is yes, you may be eligible to join the class action.
Potential Benefits of Joining the Class Action
Participating in a class action lawsuit could provide a pathway to recovery for your losses. It's important to note that engaging in this litigation process does not require individuals to serve as lead plaintiffs. Your participation means taking a stand, and you might share in any potential recovery without active involvement in the proceedings.
Time-Sensitive Information
Keep in mind that individuals interested in serving as lead plaintiffs must take action by a specific date—September 15, 2025. If you're considering this option, it’s crucial to file necessary documents promptly. Otherwise, you remain a passive member of the class.
No Financial Burden to Join
Another reassuring factor for shareholders is that all representation operates on a contingency fee basis. This means you incur no fees or expenses unless there's a recovery. That makes participating risk-free concerning financial obligation.
About Bernstein Liebhard LLP
For over three decades, Bernstein Liebhard LLP has made a significant mark in the legal arena, recovering over $3.5 billion for its clients. Their expertise includes working not only with individual investors but also representing large public pension funds. The firm has accrued numerous accolades for its achievements, securing a spot on The National Law Journal's "Plaintiffs' Hot List" multiple times.
Contacting Bernstein Liebhard
If you wish to learn more about your options or have any questions regarding this lawsuit, please reach out to Peter Allocco, the Investor Relations Manager. You can connect with him at (212) 951-2030 or email at pallocco@bernlieb.com.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit addresses allegations of misleading safety and efficacy data related to Capricor Therapeutics’ primary drug candidate.
How can I join the class action?
You can join by confirming your investment during the specified time frame and contacting the legal team for more information.
Is there a cost to participate in the lawsuit?
No, participation is on a contingency basis, which means there are no upfront costs.
What if I do not want to be a lead plaintiff?
You can still join the class action without being a lead plaintiff and share in any potential recovery.
Who can I contact for more information?
You can reach out to Peter Allocco at Bernstein Liebhard LLP for any inquiries related to the class action.
